Butanedioic acid;3-(diaminomethylidene)-1,1-dimethylguanidine | 399567-24-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Butanedioic acid;3-(diaminomethylidene)-1,1-dimethylguanidine
• CAS: 399567-24-9
• 化学式: C8H17N5O4
• 分子量: 247.25
• InChiKey: UFKWZZBTOYMVIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.31
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  166
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• [EN] TRI-SALT FORM OF METFORMIN<br/>[FR] FORME À TROIS SELS DE METFORMINE
  申请人：THETIS PHARMACEUTICALS LLC

  公开号：WO2014011814A1

  公开（公告）日：2014-01-16

  Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g. , high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity.

  本文提供的三种盐化合物包括具有两个酸性功能基团和一个碱性功能基团（例如，天冬氨酸或谷氨酸）、二甲双胍和多不饱和脂肪酸，例如二十碳五烯酸或二十二碳六烯酸。这些盐可以用于治疗糖尿病、伴有脂质代谢异常（例如高三酰甘油）的糖尿病以及加重心血管并发症的糖尿病，如心律失常、心肌缺血、心肌梗死、心肌病和中风。本发明的化合物还可用于治疗肥胖症。
• [EN] COMPOSITIONS AND DOSAGE FORMS FOR ENHANCED ABSORPTION OF METFORMIN<br/>[FR] COMPOSITIONS ET FORMES POSOLOGIQUES POUR UNE ABSORPTION AMELIOREE DE METFORMINE
  申请人：ALZA CORP

  公开号：WO2005041923A1

  公开（公告）日：2005-05-12

  A complex comprised of metformin and a transport moiety, such as a fatty acid, is described. The complex has an enhanced absorption in the gastrointestinal tract, particularly the lower gastrointestinal tract. The complex, and compositions and dosage forms prepared using the complex, provide for absorption by the body of the drug through a period of ten to twenty-four hours, thus enabling a once-daily dosage form for metformin.

  描述了由二甲双胍和传输基团（如脂肪酸）组成的复合物。该复合物在胃肠道中具有增强的吸收，特别是在下消化道。该复合物以及使用该复合物制备的组合物和剂型，使药物在十至二十四小时内通过身体吸收，从而实现二甲双胍的一日一次剂量形式。
• [EN] NOVEL SALTS OF METFORMIN AND METHOD<br/>[FR] SELS DE METFORMINE ET PROCEDE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：WO1999029314A1

  公开（公告）日：1999-06-17

  (EN) Novel salts of the antidiabetic agent metformin are provided which are metformin salts of dibasic acids (2:1 molar ratio), preferably metformin (2:1) fumarate and metformin (2:1) succinate, which may be employed alone or in combination with another antihyperglycemic agent such as glyburide, for treating diabetes. A method for treating diabetes employing the novel metformin salt by itself or in combination with another antidiabetic agent is also provided.(FR) L'invention concerne des sels de metformine (antidiabétique), qui sont des sels de diacides (rapport molaire, 2:1). Il s'agit de préférence des fumarate et succinate de metformine (2:1, respectivement), utilisables séparément ou en combinaison avec un autre agent antihyperglycémiant (par exemple, glyburide), pour traiter le diabète. L'invention concerne également un procédé permettant de traiter le diabète au moyens des sels considérés, utilisés séparément ou en combinaison avec un autre antidiabétique.

  提供了一种新型的抗糖尿病药物二甲双胍的盐，其为二元酸的二甲双胍盐（摩尔比2：1），优选的为二甲双胍（2：1）富马酸盐和二甲双胍（2：1）琥珀酸盐，可单独使用或与其他抗高血糖药物如格列吡嗪联合治疗糖尿病。还提供了一种使用新型二甲双胍盐单独或与其他抗糖尿病药物联合治疗糖尿病的方法。
• [EN] COMPOSITION OF METFORMIN WITH SUCCINIC ACID OR SALTS THEREOF AND METHOD FOR TREATING DIABETES<br/>[FR] COMPOSITION DE METFORMINE AVEC DE L'ACIDE SUCCINIQUE ET LEURS SELS ET PROCEDE POUR TRAITER LE DIABETE
  申请人：POMYTKIN IGOR ANATOLIEVICH

  公开号：WO2002012177A1

  公开（公告）日：2002-02-14

  This invention relates to compositions comprising metformin and succinic acid or a pharmaceutically acceptable salt thereof. More specifically, this invention relates to compositions comprising metformin and succinic acid or a pharmaceutically acceptable salt thereof, which are presented in amounts sufficient to cause synergistic effects for the treatment of diabetes, particularly for synergistic improvement in glycemic control. Further, the invention relates to new salts of metformin, more specifically to metformin succinates and process for producing the same. Further, this invention relates to methods of treating diabetes in mammal in need thereof, which methods comprise administering to said mammal, either sepwise or in combination, synergistically effective amounts of metformin and succinic acid or a pharmaceutically acceptable salt thereof.

  本发明涉及含有二甲双胍和琥珀酸或其药学上可接受的盐的组合物。更具体地说，本发明涉及含有二甲双胍和琥珀酸或其药学上可接受的盐的组合物，其呈现出足够的量以引起协同作用，用于治疗糖尿病，特别是协同改善血糖控制。此外，本发明涉及二甲双胍的新盐，更具体地说是二甲双胍琥珀酸盐及其制备方法。此外，本发明涉及治疗需要该治疗的哺乳动物糖尿病的方法，其中所述方法包括向所述哺乳动物分别或组合地给予协同有效量的二甲双胍和琥珀酸或其药学上可接受的盐。
• Compositions and dosage forms for enhanced absorption
  申请人：Wong S.L. Patrick

  公开号：US20060094782A9

  公开（公告）日：2006-05-04

  Disclosed is controlled delivery of pharmaceutical agents and methods, dosage forms and devices therefore. In particular, formulation, dosage forms, methods and devices for enhanced absorption and controlled delivery drug compounds are disclosed.

  本发明涉及药物剂量的控制释放以及相应的方法、剂型和设备。具体而言，本发明揭示了增强吸收和控制释放药物化合物的配方、剂型、方法和设备。